Crucell N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
25 jul 2007 - 09:00
Statutaire naam
Crucell N.V.
Titel
DSM Biologics and Crucell Announce PER.C6® Licensing Deal With LFB Biotechnologies.
Bericht
Sittard/Leiden, The Netherlands, July 25, 2007 – DSM Biologics, a business unit of DSM Pharmaceutical Products and Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced a non-exclusive PER.C6® research licensing agreement with Paris, France-based LFB Biotechnologies. LFB Biotechnologies will use Crucell’s technology to develop undisclosed antibodies. No financial details were disclosed.
Gerelateerde downloads
Datum laatste update: 05 februari 2025